- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01028560
Allergy Immunotherapy for the Reduction of Asthma (AIR)
Efficacy of Allergy Immunotherapy in Preventing Asthma Morbidity in Atopic, Wheezing Children (Age 18 Months - 3 Years)
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Bronx, New York, United States, 10461
- Jacobi Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children between 18 months through 3 years who had at least 2 episodes of wheezing prior to enrolment.
- Positive skin tests or specific Immunoglobulin E (IgE) antibody titers to at least one of common airborne allergens: Dust Mite, cat, cockroach, mouse, dog, pollen (all allergy testing can be done at the screening visit at the study site).
The child must also fulfill the criteria for high risk of developing persistent asthma by meeting at least one of the following major conditions OR 2 of the following minor conditions:
- Major criteria: History of atopic dermatitis and/or parental history of asthma.
- Minor criteria: MD-diagnosed allergic rhinitis, wheezing unrelated to colds, blood eosinophils above 4%.
Exclusion Criteria:
- The child has a severe systemic condition (other than allergy or asthma) including (but not limited to) seizures, major congenital anomalies, physical and intellectual delay, cerebral palsy, chest surgery, tuberculosis, primary or secondary immunodeficiency or cardiac disorder (except a hemodynamically insignificant atrial or ventricular septum defect or heart murmur).
- The child was born following 35 or less weeks of gestation.
- Parental report that the child received oxygen for more than 5 days in the neonatal period, or required mechanical ventilation at any time since birth.
- The child fails to thrive, defined as crossing of two major growth percentile lines during the last year.
- The child has chronic lung disease of prematurity (CLDP), cystic fibrosis or any other chronic lung disease.
- The child ever received immunotherapy.
- The child ever received i.v. gammaglobulins or immunosuppressants (other than corticosteroids for asthma).
- History of a life-threatening asthma exacerbation which required intubation and mechanical ventilation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: No immunotherapy, receive standard of care asthma treatment
This group consists of children who do not receive allergy immunotherapy.
Both groups - the experimental as well as the control group receive otherwise standard of care asthma and allergy treatment
|
standard of care asthma and allergy treatment
|
Experimental: Allergen immunotherapy
This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile.
The maximum number of injections at each visit is 1-3 injections per child.
In addition to allergy immunotherapy.
this group receives standard of care asthma and allergy treatment
|
standard of care asthma and allergy treatment
Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child.
Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached.
This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy.
To increase safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months)
Time Frame: baseline and every two weeks up to end of study (up to 36 months)
|
The Asthma Severity Score is a customized score created for this study due to the lack of standardized instruments for this age group.
It takes into account asthma symptom severity and frequency, as well as asthma medication dosing and potency.
Data was collected at baseline and every 2 weeks through interviews conducted over the phone.
If the caregiver could not be reached by the phone, the interview was conducted at the next face-to face opportunity (study or injection visit).
The minimum score on this scale is 0 (no asthma symptoms and no asthma medicines used during the 14 day interview period).
The maximum score is 224 (uncontrolled severe asthma with severe cough, shortness of breath and wheezing on 14 of 14 days, using Albuterol 2 puffs 4x/day, budesonide/formoterol 160ug/4.5ug 2 puffs twice daily and Montelukast 4mg daily on 14 of 14 days).
Scores calculated from the collected data were averaged to produce one reported value at baseline and year 1, 2 and 3.
|
baseline and every two weeks up to end of study (up to 36 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Newly Gained Allergic Sensitizations as Assessed by Serum Specific Immunoglobulin E (IgE) Testing
Time Frame: Baseline and end of treatment (36 months)
|
Young children with allergies tend to develop additional environmental allergies over time.
This study investigated if allergy immunotherapy could be used to prevent the development of new allergic sensitizations.
Participants were tested for sensitivity to a panel of 8 common environmental allergens.
Testing was conducted via serum specific immunoglobulin E (IgE) testing.
A test was considered negative (non-allergic) if the specific IgE level was <0.35 kIU/L (Kilo International Units/Liter) and positive (allergic) if the levels was >0.35 kIU/L.
A "test pair" is the result of a serum IgE test, for a specific allergen, done at two different times.
Test pairs can be negative-negative, negative-positive (newly gained allergic sensitization), positive-negative (lost sensitization) or positive-positive.
Reported values indicate the total number of newly gained allergic sensitization (negative-positive) for the group.
|
Baseline and end of treatment (36 months)
|
Peripheral Blood T Regulatory Cells as a Percentage of CD4+ (Cluster of Differentiation 4) Cells
Time Frame: Baseline and every 12 months until end of treatment (36 months)
|
T regulatory cells are thought to play a role in mediating the effects of immunotherapy in increasing allergen tolerance and dampen the clinical expression of allergy.
However, existing studies have not found clear relationship between numbers of T regulatory cells in blood and effect of immunotherapy.
The aim of this analysis was to observe potential changes in T regulatory cell numbers in response to immunotherapy in this age group.
Peripheral blood cells were acquired and analyzed for T regulatory (Treg) cell markers.
In molecular biology, CD4+ (cluster of differentiation 4), a particular cell marker, is a glycoprotein found on the surface of immune cells such as T helper cells and certain groups of T regulatory cells.
Testing was done at baseline and then every 12 months.
Reported values represents the percentage of CD4+ that are Treg cells.
|
Baseline and every 12 months until end of treatment (36 months)
|
Incidence Rate of Systemic Corticosteroid Bursts (CSB) Per Child
Time Frame: From baseline through end of study (maximum 36 months)
|
Any reported use of consequent systemic corticosteroid use due to asthma exacerbation counted as one "corticosteroid burst" (CSB). For example, if a child used 5 days of prednisolone due to asthma exacerbation, this counted as one corticosteroid burst (CSB). An interval of at least 7 days was determined to be necessary to count 2 courses of systemic corticosteroids as separated bursts. The presented data reflect the intention-to-treat analysis. The time between baseline and each participant's study end time was counted towards the "years in study". The incidence rate describes the number of CSB per child per "year in study". |
From baseline through end of study (maximum 36 months)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Gabriele de Vos, M.D., M.Sc., Einstein, Jacobi Medical Center
Publications and helpful links
General Publications
- Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003;(4):CD001186. doi: 10.1002/14651858.CD001186.
- Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol. 2006 Feb;117(2):263-8. doi: 10.1016/j.jaci.2005.09.054.
- Pifferi M, Baldini G, Marrazzini G, Baldini M, Ragazzo V, Pietrobelli A, Boner AL. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy. 2002 Sep;57(9):785-90. doi: 10.1034/j.1398-9995.2002.23498.x.
- de Vos G, Viswanathan S, Pichardo Y, Nazari R, Jorge Y, Ren Z, Serebrisky D, Rosenstreich D, Wiznia A. A randomized trial of subcutaneous allergy immunotherapy in inner-city children with asthma less than 4 years of age. Ann Allergy Asthma Immunol. 2021 Apr;126(4):367-377.e5. doi: 10.1016/j.anai.2020.12.016. Epub 2021 Jan 6.
- de Vos G, Nazari R, Ferastraoaru D, Parikh P, Geliebter R, Pichardo Y, Wiznia A, Rosenstreich D. Discordance between aeroallergen specific serum IgE and skin testing in children younger than 4 years. Ann Allergy Asthma Immunol. 2013 Jun;110(6):438-43. doi: 10.1016/j.anai.2013.03.006. Epub 2013 Apr 11.
- de Vos G, Shankar V, Nazari R, Kooragayalu S, Smith M, Wiznia A, Rosenstreich D. Fear of repeated injections in children younger than 4 years receiving subcutaneous allergy immunotherapy. Ann Allergy Asthma Immunol. 2012 Dec;109(6):465-9. doi: 10.1016/j.anai.2012.10.003. Erratum In: Ann Allergy Asthma Immunol. 2013 Mar;110(3):216.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2007-280
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Standard of care
-
Johns Hopkins UniversityRecruitingCompartment Syndrome of Leg | Extracorporeal Membrane Oxygenation Complication | Limb Ischemia, Critical | Limb IschemiaUnited States
-
brett rasmussenCompleted
-
Indonesia UniversityCompletedCovid19 | AcupunctureIndonesia
-
Aventusoft, LLC.National Heart, Lung, and Blood Institute (NHLBI); Cleveland Clinic FloridaRecruitingHeart Failure (HF)United States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedSevere COVID-19Israel
-
Ruijin HospitalRecruitingCOVID-19 PneumoniaChina
-
Institut Claudius RegaudCompletedMETASTATIC CANCERFrance
-
Ziv HospitalNot yet recruiting
-
Hofseth Biocare ASAKGK Science Inc.CompletedCovid-19 | COVIDCanada, Brazil, Hungary, Mexico, Serbia
-
City University of New York, School of Public HealthNew York State Psychiatric Institute; University of KwaZulu; International Initiative... and other collaboratorsCompleted